Exogenous ketone ester
Phase 3Small molecule
Exogenous ketone ester is one of 48 small molecule programs targeting Epilepsy. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
87 competitors in Epilepsy
#DrugCompanyPhaseTrials
1Tegretol
NovartisApproved
Vimpat
UCBApproved
Fycompa
CCatalyst Biosciences
Approved
Lexapro
AbbVieApproved
Briviact
UCBPhase 3
Dilantin
VViatris Specialty LLC
Approved
Zoloft
VViatris Specialty LLC
Approved
Epidiolex
Jazz PharmaceuticalsPhase 3
Ketalar
AAultman Health Foundation
Approved
Klonopin
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Exogenous ketone ester. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSohag University